Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shu-Qing Liu

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
Gastroenterology|June 21, 2024
Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal HypertensionChang-Peng Zhu, Shu-Qing Liu, Ke-Qi Wang, et al.
Journal of Hepatology|May 12, 2026
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acidHai-Lin Xiong, Qi Zhao, Shu-Qing Liu, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
Gastroenterology|June 21, 2024
Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal HypertensionChang-Peng Zhu, Shu-Qing Liu, Ke-Qi Wang, et al.
Journal of Hepatology|May 12, 2026
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acidHai-Lin Xiong, Qi Zhao, Shu-Qing Liu, et al.
Pageof 6